ArticleInfectious diseases and therapy2026
Validation of the VIRSTA and VIRSTA+ Scores to Identify Patients with Staphylococcus aureus Bacteremia at Very Low Risk of Infective Endocarditis.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionAdherence to guideline recommendations on the use of echocardiography in all patients with Staphylococcus aureus bacteremia (SAB) is heterogeneous. This study aims to validate the VIRSTA and VIRSTA+ scores as tools for risk stratification to identify patients at low risk of infective endocarditis (IE) and support the prioritization of transthoracic echocardiography (TTE).
methodsThis is a retrospective analysis of a prospectively assembled cohort of adult patients with SAB admitted between January 2006 and December 2022. Patients who did not undergo an echocardiogram were excluded, as well as those who died within the first 48 h, those receiving antibiotic treatment during blood culture collection, and individuals without recorded time to positivity (TTP). VIRSTA and VIRSTA+ scores were calculated from clinical records, and their diagnostic performance was assessed. IE diagnosis, defined using modified Duke criteria, was compared between patients classified as low and high risk according to these scores.
resultsOf a total of 1668 episodes diagnosed with SAB, 798 adult patients were included in the final analysis. Median (interquartile range [IQR]) TTP was 8 (7-11) h for IE cases and 12 (9-15) h for non-IE cases. In VIRSTA ≥ 3 episodes, IE was observed in 108 (19%) patients, compared with 1/238 (0.4%) with VIRSTA < 3 corresponding to a sensitivity of 99%, a specificity of 34.4% with a positive predictive value of 19.3%, and a negative predictive value (NPV) of 99.5%. The single patient with IE and a VIRSTA < 3 had a TTP < 11.5 h. Accordingly, the NPV of VIRSTA+ achieved 100%.
conclusionsVIRSTA and VIRSTA+ demonstrated high NPV for risk stratification in SAB, suggesting that they could help prioritize procedures and guide decision-making in clinical practice, particularly in resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.